Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096797 | 0.84 | IKBKB (0.76) | IKBKB | |
| SCHEMBL5099737 | 0.84 | IKBKB (0.67) | IKBKB | |
| SCHEMBL5099661 | 0.83 | IKBKB (0.79) | IKBKB | |
| SCHEMBL5099453 | 0.83 | IKBKB (0.63) | IKBKB | |
| SCHEMBL5099664 | 0.81 | IKBKB (0.64) | IKBKB | |
| SCHEMBL4089013 | 0.77 | CHEK1 (1.00) | IKBKBCHEK1 | |
| SCHEMBL5554786 | 0.76 | IKBKB (0.67) | IKBKB | |
| SCHEMBL23827455 | 0.74 | APP (0.51) | — | |
| SCHEMBL6509621 | 0.74 | SMN1; SMN2 (0.65) | IKBKBCHEK1 | |
| SCHEMBL560529 | 0.74 | IKBKB (0.52) | IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375131-B2 | NF-κB inhibitors | SMITHKLINEBEECHAM CORP. (US) | 2008-05-20 | — | — | US | claimed |
| EP-1532133-A4 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | claimed |
| US-20050165087-A1 | For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease | CALLAHAN JAMES F (US) | 2005-07-28 | — | — | US | claimed |
| EP-1532133-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2003104218-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | claimed |
| US-7375131-B2 | NF-κB inhibitors | SMITHKLINEBEECHAM CORP. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1532133-A4 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050165087-A1 | For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease | CALLAHAN JAMES F (US) | 2005-07-28 | — | — | US | disclosed |
| EP-1532133-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2003104218-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165087-A1 | For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease | NFKBIA, IKBKG, IKBKE | IKBKB 4/4885CHEK1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.